Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2014

Simon MS, Leff JA, Pandya A, Cushing M, Shaz BH, Calfee DP, et al. Cost-effectiveness of blood donor screening for Babesia microti in endemic regions of the United States. Transfusion. 2014;54(3 Pt 2):889-99.

Pekkonen P, Järviluoma A, Zinovkina N, Cvrljevic A, Prakash S, Westermarck J, et al. KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. Cell Cycle. 2014;13(23):3670-84.

Magro CM, Hagen JW, Crowson AN, Liu YC, Mihm M, Drucker NM, et al. Hypopigmented interface T-cell dyscrasia: a form of cutaneous T-cell dyscrasia distinct from hypopigmented mycosis fungoides. J Dermatol. 2014;41(7):609-17.

Vogt AP, Cohen C, Siddiqui MT. p40 (ΔNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a review and comparative analysis. Diagn Cytopathol. 2014;42(5):453-8.

Flavin R, Pettersson A, Hendrickson WK, Fiorentino M, Finn S, Kunz L, et al. SPINK1 protein expression and prostate cancer progression. Clin Cancer Res. 2014;20(18):4904-11.

Lohr JG, Adalsteinsson VA, Cibulskis K, Choudhury AD, Rosenberg M, Cruz-Gordillo P, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol. 2014;32(5):479-84.

Hagen JW, Magro CM. Indolent CD8+ lymphoid proliferation of the face with eyelid involvement. Am J Dermatopathol. 2014;36(2):137-41.

Vitolo U, Chiappella A, Franceschetti S, Carella AM, Baldi I, Inghirami G, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15(7):730-7.

Park K, Chen Z, MacDonald TY, Siddiqui J, Ye H, Erbersdobler A, et al. Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. Hum Pathol. 2014;45(10):2136-43.

González-Billalabeitia E, Seitzer N, Song SJ, Song MS, Patnaik A, Liu X-, et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014;4(8):896-904.